Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI
Lancet Oncol. 2019 20 (10): 1386-1394

PMID: 31427205 · DOI:10.1016/S1470-2045(19)30513-3

MeSH Terms (20)

Aged Algorithms Antineoplastic Agents Antineoplastic Agents, Immunological Axitinib Carcinoma, Renal Cell Dehydration Diarrhea Fatigue Female Humans Hypertension Ipilimumab Kidney Neoplasms Male Middle Aged Nivolumab Progression-Free Survival Response Evaluation Criteria in Solid Tumors Retreatment

Connections (1)

This publication is referenced by other Labnodes entities: